<DOC>
	<DOCNO>NCT01019954</DOCNO>
	<brief_summary>This study evaluate safety find high tolerable dose Levulan® Photodynamic Therapy ( PDT ) premalignant tumor head neck . Subjects receive Levulan® mouth undergo PDT . Levulan® go throughout body , get retained cancer cell non-cancer cell . After 4-6 hour , target area treat laser light activate Levulan® kill cell contain .</brief_summary>
	<brief_title>Photodynamic Therapy Early Head Neck Tumors</brief_title>
	<detailed_description>Overall Objectives : The primary objective study evaluate toxicity associate Levulan®-mediated photodynamic therapy pre-malignant head neck lesion , evaluate toxicity continuous vs. fractionate light treatment . The secondary objective assess efficacy Levulan®-mediated photodynamic therapy pre-malignant head neck lesion , assess efficacy fractionate versus continuous light treatment .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Study subject histologic diagnosis erythroplakia dysplasia , severe dysplasia , carcinoma insitu head neck . Study subject carcinoma insitu eligible situation standard therapy indicate . ECOG performance status 02 . Males females 18 year age old . Study subject capable provide informed consent indicate understanding potential risk , benefit complication propose treatment . Premalignant lesion final pathologic evaluation note suspicion presence focal microinvasion predominant lesion premalignant . Clinical assessment depth lesion confirm lesion 's clinical depth consistent pathologic evaluation identifies suspicion presence focal microinvasion . Agreement treat surgeon suspicion presence focal microinvasion treat without surgical resection . Study subject target lesion/area invasive squamous cell carcinoma head neck great 1.5 mm tissue surface . Study subject invasive squamous cell carcinoma head neck . Study subject pregnant lactating . Study subject platelet count le 100,000/cubic mm . Study subject refuse provide inform consent ( see 3.4 ) . Study subject elevate aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase , total bilirubin level &gt; 2X normal history chronic liver disease cirrhosis liver . Study subject significant cardiovascular history evaluation cardiologist deems study subject risk hypotension may occur oral administration Levulan® . Study subject porphyria hypersensitivity porphyrin . Study subject adverse reaction ondansetron lorazepam . Study subject abnormal baseline creatinine level diagnose kidney disease . Study subject medical history immune suppression . This include patient past transplantation require ongoing immunosuppressive medication also include subject HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Adults premalignant head neck tumor adults Carcinoma situ head neck standard therapy indicate</keyword>
</DOC>